Decreased CCAAT/enhancer binding protein β expression inhibits the growth of glioblastoma cells

Neuroscience

Volumn 176, Issue , 2011, Pages 110-119

  Aguilar Morante, D ^a   Cortes Canteli, M ^a   Sanz Sancristobal, M ^a   Santos, A ^b   Perez Castillo, A ^a  

^a CSIC   (Spain)

^b UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

Author keywords

C EBP ; Glioblastoma; Invasion; Proliferation; ShRNA

Indexed keywords

ALPHA3 INTEGRIN; APOPTOTIC PROTEASE ACTIVATING FACTOR 1; ATM PROTEIN; BETA3 INTEGRIN; BRCA1 PROTEIN; BRCA2 PROTEIN; CALVASCULIN; CCAAT ENHANCER BINDING PROTEIN BETA; CD146 ANTIGEN; CHECKPOINT KINASE 1; CHECKPOINT KINASE 2; CYCLIN DEPENDENT KINASE INHIBITOR 1B; CYCLINE; PLASMINOGEN ACTIVATOR; SHORT HAIRPIN RNA; UROKINASE RECEPTOR; VASCULOTROPIN C;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRAIN TUMOR; CANCER CELL CULTURE; CANCER INHIBITION; CELL CYCLE ARREST; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL CYCLE S PHASE; CELL LABELING; CELL MIGRATION; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; DOWN REGULATION; GLIOBLASTOMA; IMMUNOHISTOCHEMISTRY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEIN FUNCTION; RNA INTERFERENCE; TUMOR VOLUME;

ANIMALS; BLOTTING, WESTERN; BRAIN NEOPLASMS; CCAAT-ENHANCER-BINDING PROTEIN-BETA; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GLIOBLASTOMA; IMMUNOHISTOCHEMISTRY; MALE; MICE; MICE, INBRED C57BL; NEOPLASM INVASIVENESS; POLYMERASE CHAIN REACTION; RNA INTERFERENCE;

EID: 79851513852     PISSN: 03064522     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuroscience.2010.12.025     Document Type: Article

References (43)

1. Alberini C.M., Ghirardi M., Metz R., Kandel E.R. C/EBP is an immediate-early gene required for the consolidation of long-term facilitation in Aplysia. Cell 1994, 76:1099-1114.
2. Benedetti S., Pirola B., Pollo B., Magrassi L., Bruzzone M.G., Rigamonti D., Galli R., Selleri S., Di Meco F., De Fraja C., Vescovi A., Cattaneo E., Finocchiaro G. Gene therapy of experimental brain tumors using neural progenitor cells. Nat Med 2000, 6:447-450.
3. Bottomley P.A. Spatial localization in NMR spectroscopy in vivo. Ann N Y Acad Sci 1987, 508:333-348.
4. Buck M., Turler H., Chojkier M. LAP (NF-IL-6), a tissue-specific transcriptional activator, is an inhibitor of hepatoma cell proliferation. EMBO J 1994, 13:851-860.
5. Bundy L.M., Sealy L. CCAAT/enhancer binding protein beta (C/EBPbeta)-2 transforms normal mammary epithelial cells and induces epithelial to mesenchymal transition in culture. Oncogene 2003, 22:869-883.
6. Carro M.S., Lim W.K., Alvarez M.J., Bollo R.J., Zhao X., Snyder E.Y., Sulman E.P., Anne S.L., Doetsch F., Colman H., Lasorella A., Aldape K., Califano A., Iavarone A. The transcriptional network for mesenchymal transformation of brain tumours. Nature 2010, 463:318-325.
7. Cortes-Canteli M., Luna-Medina R., Sanz-Sancristobal M., Alvarez-Barrientos A., Santos A., Perez-Castillo A. CCAAT/enhancer binding protein beta deficiency provides cerebral protection following excitotoxic injury. J Cell Sci 2008, 121:1224-1234.
8. Cortes-Canteli M., Pignatelli M., Santos A., Perez-Castillo A. CCAAT/enhancer-binding protein beta plays a regulatory role in differentiation and apoptosis of neuroblastoma cells. J Biol Chem 2002, 277:5460-5467.
9. Cortes-Canteli M., Wagner M., Ansorge W., Perez-Castillo A. Microarray analysis supports a role for CCAAT/enhancer-binding protein-beta in brain injury. J Biol Chem 2004, 279:14409-14417.
10. DeAngelis L.M. Brain tumors. N Engl J Med 2001, 344:114-123.
11. Edwards E., Geng L., Tan J., Onishko H., Donnelly E., Hallahan D.E. Phosphatidylinositol 3-kinase/Akt signaling in the response of vascular endothelium to ionizing radiation. Cancer Res 2002, 62:4671-4677.
12. El Andaloussi A., Sonabend A.M., Han Y., Lesniak M.S. Stimulation of TLR9 with CpG ODN enhances apoptosis of glioma and prolongs the survival of mice with experimental brain tumors. Glia 2006, 54:526-535.
13. Fomchenko E.I., Holland E.C. Mouse models of brain tumors and their applications in preclinical trials. Clin Cancer Res 2006, 12:5288-5297.
14. Hanlon M., Sealy L. Ras regulates the association of serum response factor and CCAAT/enhancer-binding protein beta. J Biol Chem 1999, 274:14224-14228.
15. Hennig J., Nauerth A., Friedburg H. RARE imaging: a fast imaging method for clinical MR. Magn Reson Med 1986, 3:823-833.
16. Homma J., Yamanaka R., Yajima N., Tsuchiya N., Genkai N., Sano M., Tanaka R. Increased expression of CCAAT/enhancer binding protein beta correlates with prognosis in glioma patients. Oncol Rep 2006, 15:595-601.
17. Kjaergaard J., Tanaka J., Kim J.A., Rothchild K., Weinberg A., Shu S. Therapeutic efficacy of OX-40 receptor antibody depends on tumor immunogenicity and anatomic site of tumor growth. Cancer Res 2000, 60:5514-5521.
18. Li W., Kessler P., Yeger H., Alami J., Reeve A.E., Heathcott R., Skeen J., Williams B.R. A gene expression signature for relapse of primary wilms tumors. Cancer Res 2005, 65:2592-2601.
19. Luna-Medina R., Cortes-Canteli M., Sanchez-Galiano S., Morales-Garcia J.A., Martinez A., Santos A., Perez-Castillo A. NP031112, a thiadiazolidinone compound, prevents inflammation and neurodegeneration under excitotoxic conditions: potential therapeutic role in brain disorders. J Neurosci 2007, 27:5766-5776.
20. Menard C., Hein P., Paquin A., Savelson A., Yang X.M., Lederfein D., Barnabe-Heider F., Mir A.A., Sterneck E., Peterson A.C., Johnson P.F., Vinson C., Miller F.D. An essential role for a MEK-C/EBP pathway during growth factor-regulated cortical neurogenesis. Neuron 2002, 36:597-610.
21. Miyatake S., Martuza R.L., Rabkin S.D. Defective herpes simplex virus vectors expressing thymidine kinase for the treatment of malignant glioma. Cancer Gene Ther 1997, 4:222-228.
22. Nadeau S., Hein P., Fernandes K.J., Peterson A.C., Miller F.D. A transcriptional role for C/EBP beta in the neuronal response to axonal injury. Mol Cell Neurosci 2005, 29:525-535.
23. Paxinos G., Franklin K. The mouse brain in stereotaxic coordinates 2001, Academic Press, San Diego.
24. Pignatelli M., Cortes-Canteli M., Lai C., Santos A., Perez-Castillo A. The peroxisome proliferator-activated receptor gamma is an inhibitor of ErbBs activity in human breast cancer cells. J Cell Sci 2001, 114:4117-4126.
25. Poli V. The role of C/EBP isoforms in the control of inflammatory and native immunity functions. J Biol Chem 1998, 273:29279-29282.
26. Ramji D.P., Foka P. CCAAT/enhancer-binding proteins: structure, function and regulation. Biochem J 2002, 365:561-575.
27. Rask K., Thorn M., Ponten F., Kraaz W., Sundfeldt K., Hedin L., Enerback S. Increased expression of the transcription factors CCAAT-enhancer binding protein-beta (C/EBBeta) and C/EBzeta (CHOP) correlate with invasiveness of human colorectal cancer. Int J Cancer 2000, 86:337-343.
28. Robinson G.W., Johnson P.F., Hennighausen L., Sterneck E. The C/EBPbeta transcription factor regulates epithelial cell proliferation and differentiation in the mammary gland. Genes Dev 1998, 12:1907-1916.
29. Screpanti I., Romani L., Musiani P., Modesti A., Fattori E., Lazzaro D., Sellitto C., Scarpa S., Bellavia D., Lattanzio G. Lymphoproliferative disorder and imbalanced T-helper response in C/EBP beta-deficient mice. EMBO J 1995, 14:1932-1941.
30. Schuster M.B., Porse B.T. C/EBPalpha: a tumour suppressor in multiple tissues?. Biochim Biophys Acta 2006, 1766:88-103.
31. Seagroves T.N., Krnacik S., Raught B., Gay J., Burgess-Beusse B., Darlington G.J., Rosen J.M. C/EBPbeta, but not C/EBPalpha, is essential for ductal morphogenesis, lobuloalveolar proliferation, and functional differentiation in the mouse mammary gland. Genes Dev 1998, 12:1917-1928.
32. Sebastian T., Malik R., Thomas S., Sage J., Johnson P.F. C/EBPbeta cooperates with RB: E2F to implement Ras(V12)-induced cellular senescence. EMBO J 2005, 24:3301-3312.
33. Shuman J.D., Sebastian T., Kaldis P., Copeland T.D., Zhu S., Smart R.C., Johnson P.F. Cell cycle-dependent phosphorylation of C/EBPbeta mediates oncogenic cooperativity between C/EBPbeta and H-RasV12. Mol Cell Biol 2004, 24:7380-7391.
34. Sterneck E., Johnson P.F. CCAAT/enhancer binding protein beta is a neuronal transcriptional regulator activated by nerve growth factor receptor signaling. J Neurochem 1998, 70:2424-2433.
35. Sterneck E., Zhu S., Ramirez A., Jorcano J.L., Smart R.C. Conditional ablation of C/EBP beta demonstrates its keratinocyte-specific requirement for cell survival and mouse skin tumorigenesis. Oncogene 2006, 25:1272-1276.
36. Sundfeldt K., Ivarsson K., Carlsson M., Enerback S., Janson P.O., Brannstrom M., Hedin L. The expression of CCAAT/enhancer binding protein (C/EBP) in the human ovary in vivo: specific increase in C/EBPbeta during epithelial tumour progression. Br J Cancer 1999, 79:1240-1248.
37. Taubenfeld S.M., Milekic M.H., Monti B., Alberini C.M. The consolidation of new but not reactivated memory requires hippocampal C/EBPbeta. Nat Neurosci 2001, 4:813-818.
38. Tkac I., Starcuk Z., Choi I.Y., Gruetter R. In vivo 1H NMR spectroscopy of rat brain at 1 ms echo time. Magn Reson Med 1999, 41:649-656.
39. Vinson C.R., Sigler P.B., McKnight S.L. Scissors-grip model for DNA recognition by a family of leucine zipper proteins. Science 1989, 246:911-916.
40. Wessells J., Yakar S., Johnson P.F. Critical prosurvival roles for C/EBP{beta} and insulin-like growth factor I in macrophage tumor cells. Mol Cell Biol 2004, 24:3238-3250.
41. Zagzag D., Miller D.C., Chiriboga L., Yee H., Newcomb E.W. Green fluorescent protein immunohistochemistry as a novel experimental tool for the detection of glioma cell invasion in vivo. Brain Pathol 2003, 13:34-37.
42. Zhu S., Oh H.S., Shim M., Sterneck E., Johnson P.F., Smart R.C. C/EBPbeta modulates the early events of keratinocyte differentiation involving growth arrest and keratin 1 and keratin 10 expression. Mol Cell Biol 1999, 19:7181-7190.
43. Zhu S., Yoon K., Sterneck E., Johnson P.F., Smart R.C. CCAAT/enhancer binding protein-beta is a mediator of keratinocyte survival and skin tumorigenesis involving oncogenic ras signaling. Proc Natl Acad Sci U S A 2002, 99:207-212.